Final height of growth hormone-treated GH-deficient children and girls with Turner's syndrome: the Dutch experience. The Dutch Advisory Group on Growth Hormone.

In the Dutch growth hormone (GH) registration database there are currently 552 GH-deficient children being treated, subcutaneously, with recombinant human GH six to seven times per week. Of those, 112 who have been treated for at least 2 years have reached final height. Mean age at start of therapy was 11.70 years. Mean GH dose was 15.5 IU/m(2) body surface per week. Mean final height was 173.2 cm (boys) and 159.7 cm (girls) and -1.36 SD of the population mean. Of the patients, 73.2% and 63.4%, respectively, reached a final height above -2 SD of the population or within target limits. FH-SDS was higher compared with the results of earlier cohorts with different treatment regimens. Target height, GH peak value at diagnosis, age at start of GH therapy, height SDS (HSDS) at start of puberty, and duration of GH therapy were significantly correlated with final height. These results, combined with those of a prospective GH dose-response study, suggest that better long-term results can be obtained with early and prolonged treatment and if the GH dose is individually adapted to the short-term growth response. In an ongoing dose-response study, 68 girls with Turner's syndrome, aged 2-11 years, were randomized into three dosage groups with a daily GH dose of: (group A) 4 IU/m(2) body surface; (group B) 4 IU/m(2) in the first year of therapy and 6 IU/m(2) thereafter; (group C) 4 IU/m(2) in the first year, 6 IU/m(2) in the second year, and 8 IU/m(2) thereafter. After 4 years of GH therapy, girls aged 12 years or older started low-dose oestrogen therapy. After 7 years of GH therapy, mean HSDS in all three groups had increased to values above the third percentile for healthy girls. Mean final height and final height gain of 25 girls was 159.1 and 12.5 cm, 161.8 and 14.6 cm, and 162.7 and 16.0 cm in groups A, B and C respectively. These long-term and final height results are more favourable than the results of earlier Dutch Turner's syndrome studies. Possible explanations are the higher GH doses and/or the younger age at start of GH therapy.

de Muinck Keizer-Schrama S ，Van den Broeck J ，Sas T ，Hokken-Koelega A ... -  《hormone research》

Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.

Sas TC ，de Muinck Keizer-Schrama SM ，Stijnen T ，van Teunenbroek A ，Hokken-Koelega AC ，Waelkens JJ ，Massa GG ，Vulsma T ，Gerver WJ ，Reeser HM ，Delemarre-van de Waal HE ，Jansen M ，Drop SL ... -  《-》

Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner's syndrome participating in a randomized dose-response study.

Sas TC ，de Muinck Keizer-Schrama SM ，Stijnen T ，van Teunenbroek A ，van Leeuwen WJ ，Asarfi A ，van Rijn RR ，Drop SL ，Dutch Advisory Group on Growth Hormone ... -  《PEDIATRIC RESEARCH》

Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens.

van Pareren YK ，de Muinck Keizer-Schrama SM ，Stijnen T ，Sas TC ，Jansen M ，Otten BJ ，Hoorweg-Nijman JJ ，Vulsma T ，Stokvis-Brantsma WH ，Rouwé CW ，Reeser HM ，Gerver WJ ，Gosen JJ ，Rongen-Westerlaken C ，Drop SL ... -  《JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM》

The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.

Sas TC ，Cromme-Dijkhuis AH ，de Muinck Keizer-Schrama SM ，Stijnen T ，van Teunenbroek A ，Drop SL ... -  《JOURNAL OF PEDIATRICS》